


Foreword

Multiple Myeloma is a plasma cell disorder characterized by increase in plasma cells in the bone marrow, presence of abnormal monoclonal protein in plasma and/or urine and the evidence of end organ damage. The overall prognosis of this disease has remained grim. However, recent years have seen an increase in the number of therapeutic options for patients with multiple myeloma with therapies that have been shown to prolong survival.

In this review, Dr Rajkumar provides the historical perspective of the disease, diagnostic, staging and prognostic considerations and an excellent balanced summary of the therapeutic options ranging from stem cell transplant to targeted therapies. This comprehensive review provides important information about the management of patients with all stages of Multiple Myeloma that is of importance to practicing hematologists and oncologists.

—*Shivaani Kummar, MD*
Associate Editor